In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) reported that Armistice Capital has picked up 4,000,000 of common stock as of 2017-08-04.
The acquisition brings the aggregate amount owned by Armistice Capital to a total of 4,000,000 representing a 5.0% in the company.
For those not familiar with the company, Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
A glance at Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM)’s key stats reveals a current market capitalization of 53.17M based on 79.95M shares outstanding and a price at last close of 0.665.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-08-02, Seth picked up 33,333 at a purchase price of $$0.75 per share.This brings their total holding to 75,833 as of the date of the filing.
On the sell side, the most recent transaction saw Memorial unload 14,165 shares at a sale price of $1.87. This brings their total holding to 4,709,561.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.